Catalyst
Slingshot members are tracking this event:
European Medicines Agency's Committee for Medicinal Products for Human Use (CHMP) Adopts Positive Opinion of Teva's (TEVA) Trisenox in Treatment of Promyelocytic Leukemia. Final Decision Expected in ~60 Days.
Do you think this event is important to the companies below? How will it affect their stock price?
| Related Companies | Importance
|
Impact on Stocks
|
||||
|---|---|---|---|---|---|---|
| TEVA |
|
|
||||
Slingshot Insights Explained
Catalyst Date
Occurred on:
Nov 21, 2016
Occurred Source:
http://ir.tevapharm.com/phoenix.zhtml?c=73925&p=irol-newsArticle&ID=2224751
Related Projects
-
Don’t see a project related to the catalyst you care about?
Related Keywords
European Medicines Agency, Chmp, Positive Opinion, Trisenox, First Line Treatment, Low- To Intermediate Risk, Acute Promyelocytic Leukemia (apl)
